DelMar Pharmaceuticals Inc (DMPI)

4.95
NASDAQ : Health Care
Prev Close 5.14
Day Low/High 4.77 / 5.15
52 Wk Low/High 2.88 / 10.87
Avg Volume 35.60K
Exchange NASDAQ
Shares Outstanding 10.60M
Market Cap 54.50M
EPS -0.30
P/E Ratio 6.68
Div & Yield N.A. (N.A)

Latest News

DelMar Pharmaceuticals Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083

DelMar Pharmaceuticals Receives Notice Of Allowance From The US Patent And Trademark Office For Key Patent For VAL-083

DelMar now holds seven allowed United States patents and eight international patents with more than 100 additional patent filings from thirteen patent families representing patent claims covering VAL-083 to 2036

DelMar Pharmaceuticals Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting

DelMar Pharmaceuticals Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting

Proposed Pivotal Phase III Clinical Trial in bevacizumab-failed glioblastoma multiforme (GBM) to enroll 180 patients with target completion in well under two years

DelMar Pharmaceuticals Presents Data Supporting The Potential Of VAL-083 As A New Treatment For Ovarian Cancer At The 11th Biennial Ovarian Cancer Research Symposium

DelMar Pharmaceuticals Presents Data Supporting The Potential Of VAL-083 As A New Treatment For Ovarian Cancer At The 11th Biennial Ovarian Cancer Research Symposium

DelMar to work with advisors to confirm a clinical strategy with VAL-083 for the treatment of refractory ovarian cancer, either as a single-agent or in combination with other approved agents

DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer

DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer

- DelMar will hold a Business Update Call for Shareholders on Wednesday September 7, 2016 at 5 p.m. EDT -

DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016

DelMar Pharmaceuticals to Present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016

- Company will also hold a Business Update Call for Shareholders on Wednesday September 7, 2016 at 5 p.m. EDT -

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's how to trade five stocks that are ready to break out and trade higher from current levels.

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

DelMar Pharmaceuticals Shares Decline on Thursday After Being Uplisted to Nasdaq

Biotech investors have not had much to cheer about in 2016.

Shares of DelMar End Lower on First Day of Trading

Shares of DelMar End Lower on First Day of Trading

DelMar Pharmaceuticals enjoyed a bit of good news this week after its shares were uplisted to the Nasdaq Capital Market this week.

DelMar Pharmaceuticals Announces Approval For Listing On NASDAQ

DelMar Pharmaceuticals Announces Approval For Listing On NASDAQ

DMPI to Begin Trading on NASDAQ Capital Market on July 12, 2016

DelMar Pharmaceuticals Announces Reverse Stock Split In Preparation For Proposed Senior Exchange Uplisting

DelMar Pharmaceuticals Announces Reverse Stock Split In Preparation For Proposed Senior Exchange Uplisting

- Company will host its quarterly business update conference call and webcast today at 5 PM EDT -

DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares

DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares

New funds and restructuring of warrants to eliminate a significant portion of derivative liability positions Company to meet senior exchange listing requirement

FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer

FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer

New Orphan Designation is the Third Awarded to DelMar Pharmaceuticals by FDA Office of Orphan Products Development (OOPD)

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At American Association Cancer Research (AACR) Annual Meeting

DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial With VAL-083 At American Association Cancer Research (AACR) Annual Meeting

Results to date support the potential of VAL-083 as a new treatment paradigm for GBM patients who have failed or are unlikely to respond to currently available treatments

DelMar Pharmaceuticals Announces New Data Supporting The Unique Anti-cancer Mechanism Of VAL-083

DelMar Pharmaceuticals Announces New Data Supporting The Unique Anti-cancer Mechanism Of VAL-083

Unique mechanism of action takes advantage of tumor mutations; Findings provide direction for future combination therapies

DelMar's VAL-083 Demonstrates Promise In The Treatment Of Non-Small Cell Lung Cancer And Ovarian Cancer

DelMar's VAL-083 Demonstrates Promise In The Treatment Of Non-Small Cell Lung Cancer And Ovarian Cancer

MD Anderson Researchers Presented New Pre-clinical Data Today at the American Association of Cancer Research (AACR) Annual Meeting

DelMar Pharmaceuticals Announces Abstract Presentations For The American Association Cancer Research (AACR) Annual Meeting In April 2016

DelMar Pharmaceuticals Announces Abstract Presentations For The American Association Cancer Research (AACR) Annual Meeting In April 2016

Update on DelMar's Phase I/II Refractory GBM Clinical Trial with VAL-083 to be published as a late-breaking abstract on April 19, 2016

FDA Grants Second Orphan Designation For VAL-083

FDA Grants Second Orphan Designation For VAL-083

FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for VAL-083 in the treatment of medulloblastoma

DelMar Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On February 8, 2016

DelMar Pharmaceuticals To Present At The 18th Annual BIO CEO & Investor Conference On February 8, 2016

- Presentation with live webcast on Monday, February 8th at 10:00 a.m. EST -

DelMar Pharmaceuticals To Collaborate With MD Anderson Cancer Center On Development Of DelMar's VAL-083 In Brain Cancer

DelMar Pharmaceuticals To Collaborate With MD Anderson Cancer Center On Development Of DelMar's VAL-083 In Brain Cancer

- MD Anderson to initiate new clinical studies for the treatment of recurrent GBM -

DelMar Pharmaceuticals To Present At The Biotech Showcase™ 2016 On January 12, 2016

DelMar Pharmaceuticals To Present At The Biotech Showcase™ 2016 On January 12, 2016

- Presentation with live webcast on Tuesday, January 12th at 11:00 a.m. PT -